Bank of New York Mellon’s Apellis Pharmaceuticals APLS Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2026
Q2 | – | Sell |
-524,789
| Closed | -$21.1M | – | 4297 |
|
|
2026
Q1 | $21.1M | Buy |
524,789
+252,864
| +93% | +$5.45M | ﹤0.01% | 1512 |
|
|
2025
Q4 | $6.83M | Buy |
271,925
+23,731
| +10% | +$557K | ﹤0.01% | 2145 |
|
|
2025
Q3 | $5.62M | Buy |
248,194
+4,867
| +2% | +$114K | ﹤0.01% | 2248 |
|
|
2025
Q2 | $4.21M | Sell |
243,327
-85,846
| -26% | -$1.59M | ﹤0.01% | 2374 |
|
|
2025
Q1 | $7.2M | Sell |
329,173
-5,243
| -2% | -$145K | ﹤0.01% | 2025 |
|
|
2024
Q4 | $10.7M | Sell |
334,416
-9,323
| -3% | -$280K | ﹤0.01% | 1891 |
|
|
2024
Q3 | $9.91M | Sell |
343,739
-1,456
| -0.4% | -$53.9K | ﹤0.01% | 1936 |
|
|
2024
Q2 | $13.2M | Buy |
345,195
+22,273
| +7% | +$1.01M | ﹤0.01% | 1812 |
|
|
2024
Q1 | $19M | Sell |
322,922
-49,333
| -13% | -$3.14M | ﹤0.01% | 1607 |
|
|
2023
Q4 | $22.3M | Buy |
372,255
+11,968
| +3% | +$607K | ﹤0.01% | 1536 |
|
|
2023
Q3 | $13.7M | Buy |
360,287
+2,998
| +0.8% | +$132K | ﹤0.01% | 1762 |
|
|
2023
Q2 | $32.5M | Sell |
357,289
-35,107
| -9% | -$3.03M | 0.01% | 1265 |
|
|
2023
Q1 | $25.9M | Sell |
392,396
-12,643
| -3% | -$730K | 0.01% | 1412 |
|
|
2022
Q4 | $20.9M | Sell |
405,039
-3,420
| -0.8% | -$181K | ﹤0.01% | 1516 |
|
|
2022
Q3 | $27.9M | Buy |
408,459
+60,309
| +17% | +$3.57M | 0.01% | 1295 |
|
|
2022
Q2 | $15.7M | Buy |
348,150
+32,670
| +10% | +$1.49M | ﹤0.01% | 1679 |
|
|
2022
Q1 | $16M | Buy |
315,480
+17,287
| +6% | +$763K | ﹤0.01% | 1803 |
|
|
2021
Q4 | $14.1M | Buy |
298,193
+28,709
| +11% | +$1.13M | ﹤0.01% | 1914 |
|
|
2021
Q3 | $8.88M | Buy |
269,484
+7,456
| +3% | +$419K | ﹤0.01% | 2194 |
|
|
2021
Q2 | $16.6M | Buy |
262,028
+34,894
| +15% | +$1.8M | ﹤0.01% | 1845 |
|
|
2021
Q1 | $9.75M | Sell |
227,134
-27,073
| -11% | -$1.28M | ﹤0.01% | 2099 |
|
|
2020
Q4 | $14.5M | Buy |
254,207
+15,847
| +7% | +$670K | ﹤0.01% | 1807 |
|
|
2020
Q3 | $7.19M | Sell |
238,360
-5,280
| -2% | -$158K | ﹤0.01% | 2034 |
|
|
2020
Q2 | $7.96M | Buy |
243,640
+3,621
| +2% | +$116K | ﹤0.01% | 1966 |
|
|
2020
Q1 | $6.43M | Buy |
240,019
+43,820
| +22% | +$1.56M | ﹤0.01% | 1947 |
|
|
2019
Q4 | $6.01M | Buy |
196,199
+6,073
| +3% | +$168K | ﹤0.01% | 2241 |
|
|
2019
Q3 | $4.58M | Sell |
190,126
-9,931
| -5% | -$273K | ﹤0.01% | 2324 |
|
|
2019
Q2 | $5.07M | Buy |
200,057
+30,405
| +18% | +$619K | ﹤0.01% | 2326 |
|
|
2019
Q1 | $3.31M | Buy |
169,652
+16,932
| +11% | +$266K | ﹤0.01% | 2526 |
|
|
2018
Q4 | $2.02M | Buy |
152,720
+9,932
| +7% | +$152K | ﹤0.01% | 2720 |
|
|
2018
Q3 | $2.54M | Buy |
142,788
+15,621
| +12% | +$289K | ﹤0.01% | 2723 |
|
|
2018
Q2 | $2.8M | Buy |
127,167
+92,280
| +265% | +$2.12M | ﹤0.01% | 2667 |
|
|
2018
Q1 | $771K | Buy |
34,887
+15,721
| +82% | +$309K | ﹤0.01% | 3348 |
|
|
2017
Q4 | $416K | Buy |
+19,166
| New | +$282K | ﹤0.01% | 3682 |
|
Other funds holding APLS
Bank of New York Mellon's APLS Position: Q2 2026 in Review
Bank of New York Mellon sold out of Apellis Pharmaceuticals (APLS) in Q2 2026, closing a stake of 524,789 shares — an estimated $21.1M sold.
Bank of New York Mellon first reported a position in APLS in Q4 2017 and held it in 34 quarters. The position peaked at $32.5M in Q2 2023. 1 fund tracked by Wall St. Rank holds APLS as of Q2 2026.
- Bank of New York Mellon reported no remaining Apellis Pharmaceuticals position as of Q2 2026 after selling out during the quarter.
- Bank of New York Mellon sold 524,789 Apellis Pharmaceuticals shares in Q2 2026, an estimated $21.1M.
- Bank of New York Mellon first reported a position in Apellis Pharmaceuticals in Q4 2017 and held it in 34 quarters.
- Bank of New York Mellon's Apellis Pharmaceuticals position peaked at $32.5M in Q2 2023.
- 1 fund tracked by Wall St. Rank held Apellis Pharmaceuticals as of Q2 2026.
Based on Bank of New York Mellon's 13F filing for Q2 2026, filed 6 Aug 2026.